Next Science TM
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Next Science TM sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).
Next Science TM: 7 sponsored US clinical trials, 1 recruiting.
Next Science TM sponsors 7 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Onychomycosis of Toenail, with 1 trials.
Upper-quartile sponsor footprint
Next Science TM sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
7 total, page 1 of 1
Safety and Efficacy of Next Science Gel on Toenail Fungus
NCT04042857
Clinical Assessment of Next Science Solution on Gustilo and Anderson Type II and IIIA or IIIB Tibial Fractures
NCT04906642
Evaluating Wound Healing With Next Science Gel & Wash.
NCT03738579
Efficacy of BLASTX in Catheter Associated Bacteriuria Versus Standard of Care (SOC)
NCT03176394
Six Months Evaluation of Next Science Acne Creams on Facial Acne in Adult Females.
NCT03106766
A Study to Evaluate the Clinical Effect of Daily Next Science™ Acne Gel (NAG) on Mild to Moderate Facial Acne
NCT02404285
Next Science Wound Gel Efficacy in Chronic Wound Versus Standard of Care
NCT02138994
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Therapeutic Areas
What is open in the Next Science TM pipeline
1 recruiting of 7 indexed (14% open); 2 completed (29%).
Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Onychomycosis of Toenail (1 trial), 0 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Next Science TM: open-pipeline peers nationwide
Peers matched on 7 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Next Science TM sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 7 trials (± recruiting share)
- 3M · 7 trials · 0% recruiting
- 4Life Research · 7 trials · 0% recruiting
- 89bio · 7 trials · 29% recruiting
- Abbott Diagnostics Division · 7 trials · 0% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Academic and Community Cancer Research United · 14% recruiting · 42 trials
- Adaptive Biotechnologies · 14% recruiting · 7 trials
- AgelessRx · 14% recruiting · 7 trials
- Alaska Blind Child Discovery · 14% recruiting · 7 trials
Related
What to do with this Next Science TM page
7 registered trials is a research-attention snapshot, not an endorsement of Next Science TM or any single study.
- 1 of Next Science TM's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Onychomycosis of Toenail is the condition Next Science TM studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Onychomycosis of Toenail trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Next Science TM pipeline card: 7 registered trials from official public datasets.Report a data error.